FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court's August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics' favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics' motion for summar ...

Core Insights - NeoGenomics, Inc. announced the presentation of data from its RaDaR 1.0 assay for detecting molecular residual disease (MRD) at the 2025 San Antonio Breast Cancer Symposium (SABCS) [1][2] - The studies presented will focus on the role of circulating tumor DNA (ctDNA) in early breast cancer research and recurrence monitoring, highlighting its potential to provide actionable insights for patient care [2][4] Company Overview - NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu [4] - The company operates CAP-accredited and CLIA-certified laboratories across the US and in the UK, providing full-service sample processing and analysis [4] Study Presentations - The findings from the CLEVER trial indicate that RaDaR-detected ctDNA can precede clinical recurrence in high-risk breast cancer patients, with positive ctDNA often detected months before relapse [5] - The SURVIVE Phase III trial aims to evaluate whether liquid biopsy-guided follow-up using the RaDaR assay can enable earlier detection of recurrence and improve overall survival [5] - The SURVIVE HERoes trial focuses on treating patients at the point of molecular relapse, assessing if early intervention can enhance long-term outcomes in HER2-positive or HER2-low early breast cancer [5]

Core Insights - AerCap Holdings N.V. has signed lease agreements for two Airbus A321neo aircraft with My Freighter, marking AerCap's first customer in Uzbekistan [1][2] - The A321neo aircraft are scheduled for delivery in Q4 2027, which will enhance My Freighter's operational capabilities and support its expanding international network [1][2] Company Overview - AerCap is a global leader in aviation leasing, serving approximately 300 customers worldwide and is listed on the New York Stock Exchange [3] - My Freighter, based in Tashkent, Uzbekistan, is a cargo airline that operates scheduled and chartered flights across Europe, Asia, and the Middle East, specializing in transporting perishable goods and hazardous materials [4] - Centrum Air, established in January 2023, is Uzbekistan's largest private airline, operating under My Freighter's Air Operator Certificate and focusing on expanding its network and fleet [5]

Core Insights - NeoGenomics, Inc. will present new data on comprehensive genomic profiling (CGP) for myeloid malignancies at the 67th American Society of Hematology Annual Meeting in December 2025 [1] - The study highlights the effectiveness of the Neo Comprehensive Myeloid panel, a next-generation sequencing assay that aids in diagnosing and guiding treatment for myeloid cancers [2][3] Company Overview - NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, providing a comprehensive oncology-focused testing menu [5] - The company operates CAP-accredited and CLIA-certified laboratories across the US and in the UK, ensuring high-quality sample processing and analysis [5] Research Findings - The analysis involved 533 patients with myeloid disorders, revealing that CGP identified pathogenic changes earlier in about one-third of the cases, leading to diagnostic reclassification [3] - The study uncovered rare but clinically significant fusions, such as PDGFRA, PDGFRB, FGFR1, and JAK2, which informed targeted treatment decisions [3] Leadership Statement - The President and COO of NeoGenomics emphasized the company's commitment to improving cancer care by providing advanced diagnostic tools that enable personalized treatment decisions for patients with complex blood cancers [4]

Core Points - TotalEnergies has signed an agreement to merge its Upstream business with NEO NEXT Energy Limited, resulting in the formation of NEO NEXT+, where TotalEnergies will hold a 47.5% stake [1][9] - NEO NEXT+ is projected to become the largest independent oil and gas producer in the UK, with a production capacity exceeding 250,000 barrels of oil equivalent per day by 2026 [1][9] - The transaction reflects TotalEnergies' long-term commitment to the UK oil and gas sector and aims to enhance energy security [2] Company Overview - TotalEnergies has been operating in the UK for over 60 years, employing more than 1,800 people and managing approximately 27% of the UK Continental Shelf's gas production, with an average daily equity production of 121,000 barrels of oil equivalent per day expected in 2024 [4] - The company is also a significant player in the UK's energy market, providing gas and electricity to businesses and the public sector, along with electric vehicle charging solutions and various petroleum products [6] - TotalEnergies is actively pursuing an Integrated Power strategy in the UK, which includes a renewable portfolio with 1.1 GW of gross installed capacity and 4.5 GW under development in offshore wind and solar projects [5]

NeoGenomics (NasdaqCM:NEO) FY Conference December 02, 2025 02:30 PM ET Company ParticipantsWarren Stone - President and COOTony Zook - CEOConference Call ParticipantsDave Westenberg - Life Sciences Tools & Diagnostics AnalystDave WestenbergAll right. So, I'm Dave Westenberg, the Life Science Tools and Diagnostics Analyst here at Piper. Up next here we have NeoGenomics. Very happy to present NeoGenomics CEO Tony Zook and COO Warren Stone. Thank you very much for both coming. So your clinical business is perf ...

NeoGenomics FY Conference Summary Company Overview - **Company**: NeoGenomics (NasdaqCM:NEO) - **Date of Conference**: November 19, 2025 Key Points Financial Performance - **Strong Quarter**: NeoGenomics reported a strong quarter with overall revenue growth of 12% [3][5] - **Clinical Business Growth**: Clinical business, representing over 90% of total business, saw volume increase by 15% and revenue increase by 18% [3][5] - **NGS Growth**: Next-Generation Sequencing (NGS) revenue grew by 24%, primarily driven by volume rather than price [3][5] - **Average Unit Price (AUP)**: AUP increased by 3%-4% quarter over quarter and sequentially [4][5] Product Developments - **NGS Product Penetration**: Five key NGS products now represent 24% of overall clinical revenue, with expectations for continued growth [4][6] - **PanTracer Family**: Rebranding of solid tumor therapy selection portfolio under the PanTracer family has simplified messaging and improved market reception [8][9] - **MRD Market Re-entry**: NeoGenomics plans to formally launch Radar ST in the clinical setting next year, which is expected to drive future growth [5][41] Market Strategy - **Community Focus**: The company targets community oncologists, aiming to address their specific needs and pain points [12][29] - **Desiloing Model**: A new sales strategy using data triangulation to identify high-volume therapy selection test prescribers has shown a 2x improvement in closing rates [33][34] - **Pathline Integration**: The integration of Pathline lab into NeoGenomics is expected to enhance service offerings and drive growth in the Northeast region [36][39] Future Outlook - **Growth Drivers for 2026**: Anticipated growth from existing NGS portfolio, Pathline integration, and Radar ST launch [72][74] - **Pharma Business Recovery**: Expected erosion in the pharma business through 2025, with a return to growth anticipated in 2027 [59][60] - **Margin Improvement**: Focus on higher-value tests and operational efficiencies, including LIMS integration and automation, is expected to enhance margins [66][68] Additional Insights - **Market Feedback**: Positive early feedback from clinical customers regarding Radar ST, particularly concerning its sensitivity and specificity [46][49] - **Turnaround Times**: Improvements in turnaround times for assays are being implemented, with expectations to outperform previous benchmarks [50][51] - **Strategic Partnerships**: Potential partnerships in the breast cancer testing space are being explored to enhance market presence [48] Conclusion - NeoGenomics is positioned for continued growth with a strong focus on NGS and MRD markets, alongside strategic integration efforts and community-focused sales strategies. The company remains optimistic about its future performance while being cautious about overpromising results.

Core Insights - NeoGenomics, Inc. will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference, showcasing its commitment to engaging with investors [3][7]. Company Overview - NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu [2]. - The company serves a wide range of clients, including oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms, providing innovative diagnostic and predictive testing to aid in cancer diagnosis and treatment [2]. Upcoming Events - The company will present at the Stephens Annual Investment Conference in Nashville, TN, on November 19 at 1:00 pm CT [3]. - NeoGenomics will also participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, NY, on December 2 at 2:30 pm ET [3].

Core Insights - NeoGenomics will present research at ISLB 2025 demonstrating high concordance between its RaDaR ST and RaDaR 1.0 MRD assays [1] Group 1 - The presentation will include four additional posters alongside the main research findings [1]

Operations and Services - As of September 30, 2025, NeoGenomics operated CAP accredited and CLIA certified laboratories across multiple locations in the U.S. and the U.K.[123] - NeoGenomics is a leading provider of Heme oncology diagnostic testing, including molecular and NGS testing, with NGS panels being one of the fastest-growing testing areas[130] - The acquisition of Inivata in June 2021 enhanced NeoGenomics' capabilities in oncology liquid biopsy technology, expected to drive growth in the coming years[133] - The company offers a comprehensive suite of technical and professional interpretation services to meet the needs of clients requiring expert analysis of testing results[142] - NeoGenomics provides comprehensive support in oncology programs, including biomarker discovery, study design, clinical trial testing, and companion diagnostic development[135] - NeoGenomics' direct sales force is organized into ten regions in the U.S., focusing on value-based care solutions and end-to-end client experience as a growth driver[144] Financial Performance - Consolidated revenue for the three months ended September 30, 2025, was $187.8 million, an increase of $20.0 million or 11.9% compared to the same period in 2024[153] - For the nine months ended September 30, 2025, consolidated revenue reached $537.2 million, reflecting an increase of $48.6 million or 9.9% year-over-year[153] - Cost of revenue for the three months ended September 30, 2025, was $107.4 million, up 15.5% from $92.9 million in 2024[155] - Gross profit for the three months ended September 30, 2025, was $80.4 million, with a gross profit margin of 42.8%, down from 44.6% in the same period of 2024[155][159] - General and administrative expenses for the three months ended September 30, 2025, were $69.9 million, an increase of $2.9 million or 4.3% compared to 2024[161] - Research and development expenses for the three months ended September 30, 2025, increased to $8.7 million, a rise of 13.1% from $7.7 million in 2024[164] - Sales and marketing expenses for the three months ended September 30, 2025, were $21.8 million, reflecting a 6.8% increase compared to $20.4 million in 2024[168] - Net loss for the three months ended September 30, 2025, was $27.1 million, compared to a net loss of $17.7 million in the same period in 2024, resulting in a basic net loss per share of $(0.21)[179] Cash Flow and Investments - Cash provided by operating activities was $3.9 million for the nine months ended September 30, 2025, compared to cash used of $2.8 million in the same period in 2024, marking a $6.7 million increase[187] - Cash used in investing activities was $6.0 million for the nine months ended September 30, 2025, compared to cash provided of $18.3 million in the same period in 2024, primarily due to a decrease in proceeds from maturities of marketable securities[188] - Cash used in financing activities was $200.7 million for the nine months ended September 30, 2025, compared to cash provided of $4.0 million in the same period in 2024, mainly due to repayment of convertible senior notes[189] - As of September 30, 2025, the company had $164.1 million in unrestricted cash and cash equivalents available to support operational liquidity needs for at least the next 12 months[190] - Approximately $19.1 million was spent on capital equipment, software, and leasehold improvements during the nine months ended September 30, 2025[191] Future Outlook and Strategic Initiatives - The company aims to accelerate volume growth through traditional clinical and NGS modalities, targeting oncologists in the community and executing a pharmaceutical client strategy[139] - NeoGenomics expects to enhance operational efficiency and gross margin while transforming its digital ecosystem to achieve positive cash flow from operations[139] - The company anticipates an increase in research and development expenditures as it continues to invest in innovation projects and new tests[167] - The company expects higher commissions expense in the coming quarters due to the expansion of its sales representative force[170] - Capital expenditures for the year ending December 31, 2025 are anticipated to be in the range of $30.0 million to $35.0 million[191] Impairments and Interest - Impairment charges increased by $7.1 million and $27.1 million for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024[174] - Interest income decreased to $1.6 million and $7.5 million for the three and nine months ended September 30, 2025, representing a decline of 66.6% and 46.5% year-over-year, respectively[175] - Interest expense decreased to $0.6 million and $3.2 million for the three and nine months ended September 30, 2025, reflecting a decline of 63.3% and 36.8% year-over-year, respectively[177] Market and Currency Risks - The company has operations in Cambridge, United Kingdom, exposing it to foreign currency exchange risks primarily in British Pounds[197] - The company does not hedge foreign currency exchange risks and currently does not believe these risks are significant[197] - The fair value of the 2028 Convertible Notes is affected by interest rate fluctuations and the company's common stock price[195] - A 1% change in interest rates as of September 30, 2025 would not have had a material effect on the fair value of the investment portfolio[196] - The company invests in highly liquid and high-quality U.S. government and other highly credit rated debt securities to preserve principal and maximize yields[196]